- Home
- PRPL vs GNLX Comparison
PRPL vs GNLX Comparison
Compare PRPL & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPL
- GNLX
- Stock Information
- Founded
- PRPL 2010
- GNLX 2001
- Country
- PRPL United States
- GNLX United States
- Employees
- PRPL N/A
- GNLX N/A
- Industry
- PRPL Home Furnishings
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- PRPL Consumer Discretionary
- GNLX Health Care
- Exchange
- PRPL Nasdaq
- GNLX Nasdaq
- Market Cap
- PRPL 90.3M
- GNLX 184.4M
- IPO Year
- PRPL N/A
- GNLX 2023
- Fundamental
- Price
- PRPL $0.66
- GNLX $3.58
- Analyst Decision
- PRPL Buy
- GNLX Strong Buy
- Analyst Count
- PRPL 3
- GNLX 4
- Target Price
- PRPL $1.70
- GNLX $18.25
- AVG Volume (30 Days)
- PRPL 403.9K
- GNLX 174.5K
- Earning Date
- PRPL 03-13-2025
- GNLX 03-31-2025
- Dividend Yield
- PRPL N/A
- GNLX N/A
- EPS Growth
- PRPL N/A
- GNLX N/A
- EPS
- PRPL N/A
- GNLX N/A
- Revenue
- PRPL $504,838,000.00
- GNLX $8,000.00
- Revenue This Year
- PRPL N/A
- GNLX N/A
- Revenue Next Year
- PRPL $1.83
- GNLX N/A
- P/E Ratio
- PRPL N/A
- GNLX N/A
- Revenue Growth
- PRPL N/A
- GNLX N/A
- 52 Week Low
- PRPL $0.65
- GNLX $1.60
- 52 Week High
- PRPL $2.12
- GNLX $7.04
- Technical
- Relative Strength Index (RSI)
- PRPL 23.09
- GNLX 42.56
- Support Level
- PRPL $0.77
- GNLX $3.51
- Resistance Level
- PRPL $0.85
- GNLX $4.37
- Average True Range (ATR)
- PRPL 0.06
- GNLX 0.44
- MACD
- PRPL -0.02
- GNLX -0.13
- Stochastic Oscillator
- PRPL 4.60
- GNLX 12.82
About PRPL Purple Innovation Inc.
Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms, and other products. It sells its products through online channels, traditional wholesale partners and third-party online retailers.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.